Saturday 17 October 2026 Export MDT’s income statement to Excel — free account

Medtronic PLC

Medtronic PLC’s revenue for fiscal 2026 (year ended April 2026) was $36.4 billion, up 8.43% from fiscal 2025. In the quarter to July 2026, revenue grew 13.7%, EPS grew 42.0%, free cash flow grew 120.9% and total debt fell 1.59%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for three, operating cash flow growth for three.

94.75 0.70 −0.73%

Follow MDT

Alert me

Market cap: $122.1B
P/E: 23.2×
Fwd P/E: 18.7×
Dividend yield: 3.02%
F-score: 7/9
Altman Z: 2.73
Beneish M: −2.58
Dividend safety: 61/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total sells 8.92

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	—	1	—	—	—	1	1	—	1	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 122,100.00

Revenue 37,542.00

Net Income 5,269.00

Free Cash Flow 6,132.00

Net Debt 19,334.00

Current Ratio 2.07

Debt/Equity 0.55

P/E ratio 23.22

Fwd P/E 18.70

P/S ratio 3.23

P/B ratio 2.38

Past 5Y EPS Growth 7.00%

This Y EPS Growth 8.10%

Next Y EPS Growth 7.07%

Next Y revenue growth 7.18%

Next 5Y EPS Growth 7.72%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 9.29%

10-year low 10-year high

P/S against its own 10 years 9.36%

10-year low 10-year high

P/B against its own 10 years 57.10%

10-year low 10-year high

EV/Sales against its own 10 years 7.70%

10-year low 10-year high

EV/FCF against its own 10 years 10.25%

10-year low 10-year high

Dividends

Payout Ratio 0.70

Annual Dividend Rate 2.86

Annual Dividend Yield 3.02%

	total	individual payouts
2029	Powerpack
2028	Powerpack
2027	Powerpack
2026	2.86	0.71 0.72 0.72
2025	2.83	0.70 0.71 0.71 0.71
2024	2.79	0.69 0.70 0.70 0.70
2023	2.75	0.68 0.69 0.69 0.69
2022	2.67	0.63 0.68 0.68 0.68
2021	2.47	0.58 0.63 0.63 0.63
2020	2.28	0.54 0.58 0.58 0.58
2019	2.12	0.50 0.54 0.54 0.54
2018	1.96	0.46 0.50 0.50 0.50
2017	1.81	0.43 0.46 0.46 0.46
2016	1.67	0.38 0.43 0.43 0.43

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	8,005	8,965	9,220	8,819
Receivables	6,128	6,515	6,643	6,357
Inventory	5,217	5,476	5,951	6,215
Other	2,584	2,858	2,972	2,999
	21,935	23,814	24,787	24,390

	2024	2025	2026	Q'26
Payables	2,410	2,449	2,644	2,695
ST’ Debt	1,092	2,874	1,788	2,536
Other	—	—	—	—
	10,789	12,879	11,658	11,799

Compound Annual Growth %

	10y	5y	3y
Sales	2.35%	3.84%	5.21%
Cash Flow	3.46%	3.27%	6.67%
Earnings	3.10%	5.89%	8.51%
Book Value	(0.39%)	(0.60%)	(1.04%)

Revenue $m

	Jul	Oct	Jan	Apr	Year
’26	9,756	—	—	—	—
’26	8,578	8,961	9,017	9,808	36,364
’25	7,915	8,403	8,292	8,927	33,537
’24	7,702	7,984	8,089	8,589	32,364
’23	7,371	7,585	7,727	8,544	31,227
’22	7,987	7,847	7,763	8,089	31,686
’21	6,507	7,647	7,775	8,188	30,117

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jul	Oct	Jan	Apr	Year
’26	1,793	—	—	—	—
’26	1,088	925	2,744	2,573	7,330
’25	986	958	2,572	2,528	7,044
’24	875	661	2,474	2,777	6,787
’23	1,083	922	1,574	2,460	6,039
’22	1,292	1,769	2,228	2,057	7,346
’21	278	1,861	2,356	1,745	6,240

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jul	Oct	Jan	Apr	Year
’26	1,290	—	—	—	—
’26	584	457	2,300	2,085	5,426
’25	466	554	2,096	2,069	5,185
’24	521	200	2,128	2,351	5,200
’23	657	599	1,242	2,082	4,580
’22	914	1,498	1,898	1,668	5,978
’21	(56)	1,580	1,993	1,368	4,885

Fiscal quarters ending in the months shown.

EPS $

	Jul	Oct	Jan	Apr	Year
’26	1.14	—	—	—	—
’26	0.81	1.07	0.89	0.96	3.73
’25	0.80	0.99	1.01	0.82	3.61
’24	0.59	0.68	0.99	0.49	2.76
’23	0.70	0.32	0.92	0.88	2.82
’22	0.56	0.97	1.10	1.10	3.73
’21	0.36	0.36	0.94	1.00	2.66

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	69.35	76.41	81.66	72.13	98.38	75.77	68.84	75.96	79.55	73.31	Analyst estimates 2027–2029 Powerpack
	High	89.72	100.15	115.94	122.15	135.89	114.31	92.02	92.68	106.33	105.50
People
People	Employees	91,000	86,000	90,000	90,000	90,000	95,000	95,000	95,000	95,000	95,000
	Revenue/emp, $m	0.33	0.35	0.34	0.32	0.33	0.33	0.33	0.34	0.35	0.38
Income, $m
Income, $m	Revenue	29,710	29,953	30,557	28,913	30,117	31,686	31,227	32,364	33,537	36,364
	Gross margin, %	68.72	69.73	70.04	67.41	65.19	67.98	65.67	65.34	65.32	65.02
	EBT	4,602	5,675	5,197	4,055	3,895	5,517	5,364	4,837	5,628	6,136
	EBT margin, %	15.49	18.95	17.01	14.02	12.93	17.41	17.18	14.95	16.78	16.87
	Net income	4,024	3,095	4,650	4,806	3,630	5,062	3,784	3,705	4,691	4,837
	Depreciation	2,917	2,644	2,659	2,663	2,702	2,707	2,697	2,647	2,861	2,958
Per share, $
Per share, $	Revenue	21.55	22.08	22.70	21.57	22.39	23.60	23.48	24.38	26.09	28.37
	Earnings	2.92	2.29	3.44	3.57	2.67	3.75	2.83	2.77	3.63	3.75
	Cash flow	4.99	3.45	5.20	5.40	4.64	5.47	4.54	5.11	5.48	5.72
	Capex	(0.91)	(0.79)	(0.84)	(0.90)	(1.01)	(1.02)	(1.10)	(1.20)	(1.45)	(1.49)
	Free cash flow	4.08	2.67	4.36	4.49	3.63	4.45	3.44	3.92	4.03	4.23
	Book value	36.50	37.46	37.29	37.94	38.37	39.27	38.85	37.98	37.54	39.06
	Shares, m	1,379	1,357	1,346	1,341	1,345	1,342	1,330	1,328	1,286	1,282
Valuation, ×
Valuation, ×	P/E	28.58	34.99	25.82	27.35	49.03	27.50	32.04	29.18	23.35	21.65
	P/S	3.89	3.63	3.91	4.53	5.85	4.37	3.86	3.29	3.25	2.85
	P/B	2.29	2.14	2.38	2.57	3.41	2.63	2.33	2.11	2.26	2.07
	EV/Sales	4.55	4.11	4.42	5.01	6.36	4.80	4.39	3.82	3.83	3.37
	EV/FCF	24.03	34.08	23.00	24.04	39.23	25.43	29.91	23.76	24.79	22.58
Cash, $m
Cash, $m	Operating cash flow	6,880	4,684	7,007	7,234	6,240	7,346	6,039	6,787	7,044	7,330
	Capex	(1,254)	(1,068)	(1,134)	(1,213)	(1,355)	(1,368)	(1,459)	(1,587)	(1,859)	(1,904)
	Free cash flow	5,626	3,616	5,873	6,021	4,885	5,978	4,580	5,200	5,185	5,426
Balance, $m
Balance, $m	Working capital	10,609	12,896	13,495	11,665	14,039	10,665	12,624	11,146	10,935	13,129
	Total debt	33,441	25,757	25,324	24,797	26,389	24,114	24,364	25,024	28,516	27,961
	Net debt	19,733	14,530	15,476	13,849	15,572	13,541	16,405	17,019	19,551	18,741
	Shareholders’ equity	50,330	50,822	50,212	50,872	51,602	52,722	51,665	50,420	48,256	50,072
Returns, %
Returns, %	ROA	4.04	3.25	5.11	5.31	3.92	5.48	4.13	4.06	5.13	5.20
	ROIC	4.80	6.35	5.96	4.63	4.17	5.43	5.04	4.77	5.49	5.87
	ROE	7.87	6.14	9.17	9.48	7.04	9.66	7.20	7.20	9.45	9.77

Negative figures in brackets.

All 10 years →

Fiscal years to Apr 2026 · latest quarter Jul 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ABT Abbott Laboratories	$181.1B	33.9×	22.9×	+13.02% (above 0%: growing)	−47.52% (below 0%: shrinking)	+28.87% (above 0%: growing)	57.71%	13.44%	Compare
MDT Medtronic PLC	$122.1B	23.2×	18.7×	+13.73% (above 0%: growing)	+41.98% (above 0%: growing)	+120.89% (above 0%: growing)	64.99%	18.08%
SYK Stryker Corporation	$112.5B	30.3×	24.1×	+9.42% (above 0%: growing)	+43.10% (above 0%: growing)	+14.12% (above 0%: growing)	68.27%	25.18%	Compare
BSX Boston Scientific Corporation	$64.0B	17.9×	17.8×	+7.53% (above 0%: growing)	+14.81% (above 0%: growing)	+13.29% (above 0%: growing)	70.71%	21.65%	Compare
EW Edwards Lifesciences Corporation	$50.8B	49.8×	30.7×	+13.63% (above 0%: growing)	−26.32% (below 0%: shrinking)	+142.84% (above 0%: growing)	77.46%	29.48%	Compare
DXCM DexCom, Inc.	$33.1B	33.2×	29.8×	+13.08% (above 0%: growing)	+41.30% (above 0%: growing)	−11.68% (below 0%: shrinking)	63.44%	24.33%	Compare
GEHC GE HealthCare Technologies Inc.	$31.8B	16.0×	14.4×	+5.75% (above 0%: growing)	+16.98% (above 0%: growing)	+750.00% (above 0%: growing)	41.17%	13.96%	Compare
PHG Koninklijke Philips N.V.	$24.9B	18.8×	11.2×	+2.94% (above 0%: growing)	+56.67% (above 0%: growing)	+49.74% (above 0%: growing)	49.31%	13.99%	Compare
STE STERIS plc	$21.9B	27.1×	23.6×	+7.30% (above 0%: growing)	+13.89% (above 0%: growing)	−14.36% (below 0%: shrinking)	45.84%	19.15%	Compare
Median of peers	$41.9B	28.7×	23.3×	+8.48%	+15.90%	+21.50%	60.58%	20.40%

All 149 Medical Devices stocks →

Medtronic PLC (MDT) key facts

Strength: Medtronic PLC’s revenue for fiscal 2026 (year ended April 2026) was $36.4 billion, up 8.43% from fiscal 2025.
Strength: Net income was $4.8 billion, or $3.75 per share (basic), a net margin of 13.2%.
Medtronic PLC (MDT) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, MDT traded at $94.75, a market capitalization of $122.1 billion.
At that price the stock trades at 23.2× trailing-twelve-month earnings and 3.2× sales; its P/E is higher than 9% of its own readings over the past ten years.
Medtronic PLC pays an annual dividend of $2.86 per share, a yield of 3.02%, with a payout ratio of 70.4%.
Return on equity was 9.77% and debt-to-equity 0.55.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 2.73 (grey zone) for fiscal 2026.